U.S. CDC probes new death, hospitalization after J&J vaccine shots - officials


By Kanishka Singh

April 22 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) is investigating the death of an Oregon woman and the hospitalization of another in Texas after receiving Johnson & Johnson's JNJ.N COVID-19 vaccine, state health officials said.

The incidents come as advisers to the CDC are set to meet on Friday to consider whether it is safe to resume injections of the single-dose vaccine, while senior health officials prepare for a green light.

CDC Director Rochelle Walensky had said on Monday the agency was reviewing reports of a handful of potential cases of severe side effects among people who received the shot, in addition to those that led to a pause in its use.

The CDC notified Oregon about the incident on Tuesday and Texas on Wednesday, the two states' health officials said.

The Oregon woman, who is in her 50s, received the vaccine before the pause order on its use was issued, the state's health authority said in a statement. (

She developed "a rare but serious blood clot within two weeks following vaccination," seen in combination with very low platelets, the Oregon Health Authority added.

It warned that blame could not be assigned until its investigation was complete.

Separately, a woman in Texas who received J&J's vaccine has been hospitalized for symptoms similar to those of six people who recently suffered blood clots after taking the shot in the United States, a Texas health agency spokesman said.

Last week, U.S. health agencies recommended a pause in the use of the vaccine after six rare cases of blood clots.

On Tuesday, the European Medicines Agency (EMA) said it found a possible link between J&J's vaccine and rare blood clotting issues in adults who got doses in the United States, but added that the benefits of the shot outweighed the risks.

U.S. pauses use of J&J vaccine over rare blood clots, rollout delayed in Europe

EU regulator backs J&J shot, finds possible link to clots

(Reporting by Kanishka Singh and Shubham Kalia in Bengaluru, additional reporting by Ankur Banerjee; Editing by Ana Nicolaci da Costa, Clarence Fernandez and Sriraj Kalluvila)

((; +91 8061822801;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.